A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Researchers want to learn if MK-1084, the study medicine, can treat advanced or metastatic non-squamous NSCLC. MK-1084 is a targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread. The goals of this study are to learn: * About the safety of MK-1084 and if people tolerate it when taken with other treatments * How many people have the cancer respond (get smaller or go away) to the treatments
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 3 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Oct 1, 2026 · Source: ClinicalTrials.gov
The study is currently accepting participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Merck Sharp & Dohme LLC
- Interventions being studied
- Drug: MK-1084; Biological: Patritumab deruxtecan; Biological: Sacituzumab tirumotecan; Biological: Cetuximab; Drug: Rescue Medications
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- The main inclusion criteria include but are not limited to the following:
- Has histologically or cytologically confirmed diagnosis of advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
- Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene (KRAS) mutation of glycine to cysteine at codon 12 (G12C) mutations
- Has documented disease progression after receiving 1-2 prior lines of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapy and platinum-based chemotherapy
- Has provided tumor tissue for biomarker analysis from an archival sample or a newly obtained core or excisional biopsy of a tumor lesion not previously irradiated
- Participants with human immunodeficiency virus (HIV) infection must have well-controlled HIV on antiretroviral therapy (ART) per protocol
The main
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Clermont Oncology Center ( Site 0041)Clermont, Florida
- University of Illinois Hospital & Health Sciences System ( Site 0044)Chicago, Illinois
- Providence Portland Medical Center ( Site 0043)Portland, Oregon
- Providence Oncology and Hematology Care Clinic - Westside ( Site 0059)Portland, Oregon
- Hospital São Lucas da PUCRS ( Site 0283)Porto Alegre, Rio Grande do Sul
- Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0282)Barretos, São Paulo
- Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0286)São José do Rio Preto, São Paulo
- Hospital Paulistano ( Site 0280)São Paulo, São Paulo
- Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0162)Santiago, Region M. de Santiago
- Fundación Arturo López Pérez ( Site 0161)Santiago, Region M. de Santiago
- Bradfordhill ( Site 0160)Santiago, Region M. de Santiago
- Guangdong Provincial People s Hospital ( Site 0300)Guangzhou, Guangdong
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 1, 2026. Always confirm current availability with the study team.